A Phase 4 interventional study of Measles vaccine and Oral polio vaccine in Measles Vaccination, Oral Polio Vaccine and Non-specific/Heterologous Effects of Vaccines, sponsored by Bandim Health Project. Completed at 1 site in Guinea-Bissau. Open to participants aged 0 Months to 59 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-03.
Sponsored by Bandim Health Project · Phase 4, Interventional, and Prevention
The world is set on eradicating measles and polio infections in the coming decade. Once both infections are under control, campaigns with measles and oral polio vaccines will be phased out. This might do more harm than good for child survival in low-income countries. Studies from the Bandim Health Project in Guinea-Bissau, and elsewhere, have revealed, that the live measles and oral polio vaccines have beneficial non-specific effects, i.e. effects on child morbidity and mortality unrelated to prevention of the targeted diseases.
The campaigns are presumed to be most beneficial for children not reached by routine vaccination programs, as they are not already protected. However, studies show that prior routine or campaign vaccination may boost resistance against unrelated infections. If we phase out measles and oral polio campaigns after eradicating their target infections without considering the impact on child survival, the drastic decline in child mortality since 1990 could change direction. We will conduct the first cluster randomized controlled trial to evaluate the effect of measles and oral polio campaigns on general child morbidity and mortality via the Bandim Health Project. Bandim Health Project runs a Health and Demographic Surveillance System in Guinea-Bissau since 1978 and assesses child health interventions' real-life effects, via continuous registration of all interventions given to all children, and follow-up of individuals. We will conduct the trials in rural Guinea-Bissau monitoring all nine health regions.
The hypotheses are:
RECAMP-MV: Measles vaccination campaign in Guinea-Bissau reduce morbidity and mortality among children between 9 and 59 months of age by 80% during the subsequent 18 months in a context of limited measles infection.
RECAMP-OPV: Oral polio vaccination campaigns in Guinea-Bissau reduce morbidity and mortality among children between 0 and 8 months of age by 25% during the subsequent 12 months in a context with no polio infection.
Originally, the trials were meant to be implemented in 182 clusters, enrolling 21000 children. Following revised sample size calculations and discussions with the Data Safety and Monitoring Board, the number of clusters were increased to 222 and the planned number of enrolments increased from 21,000 to 28,000 (RECAMP-MV: 18000, RECAMP-OPV: 10000).
To explore the hypothesis that at least part of the beneficial non-specific effects of OPV is driven by changes in the gut and/or respiratory microbiome, we will collect microbiome samples in a sub-group:
A nasal swab and a rectal swab will be collected from 50 infants allocated to the intervention group, and 50 infants allocated to the control group. Two sample will be collected for each infant one when recruited for RECAMP-OPV and a second two months later.
Inclusion Criteria: Children aged 0-59 months living with families registered in the rural Bandim Health Project Health and Demographic Surveillance Site are included, provided a parent/guardian consent.
Exclusion Criteria:
OR
OR
OR
OR
In intervention villages children will be weighed and receive standard measles vaccine in one dose if they are between 9-59 months old.
Biological: Measles vaccine
In intervention villages children will be weighed and receive standard oral polio vaccine in one or two doses if they are between 0-8 months old.
Biological: Oral polio vaccine
In control villages children aged 9-59 months acting as controls to the MV-intervention arm will be weighed only.
In control villages children aged 0-8 months acting as controls to the OPV-intervention arm will be weighed only.
A measles vaccine prequalified from the World Health Organization will be administered in one dose by deep subcutaneous injection into the left subscapular region by a local nurse.
A bivalent oral polio vaccine prequalified by the World Health Organization will be administered in one or two doses directly into the mouth of the vaccinee with two drops per dose by a local nurse.
Composite outcome: mortality and hospital admission (measured as a rate)
Death (registered through follow-up visits, verified by verbal autopsies) or first admission (overnight stay at hospital registered by interview at follow up visits) Correction: Non-accidental death (registered through follow-up visits, verified by verbal autopsies) or first admission not caused by accident (overnight stay at hospital registered by interview at follow up visits) The outcomes were correctly specified in the protocol paper and analysis plan (doi: 10.1186/s12889-019-7813-y)
Time frame: Enrolment to end of study (longest follow-up 2 years)
Nutritional status
Mid-upper-arm-circumference registered with measurement tape as per UNICEF recommendations
Time frame: Enrolment to end of study (longest follow-up 2 years)
Mortality
Death (registered through follow-up visits, verified by verbal autopsies) Corrections: Non-accidental death (registered through follow-up visits, verified by verbal autopsies) The outcome was correctly specified in the protocol paper and analysis plan (doi: 10.1186/s12889-019-7813-y)
Time frame: Enrolment to end of study (longest follow-up 2 years)
Hospital admission
admission (overnight stay at hospital registered by interview at follow up visits) Correction: admission not caused by accident (overnight stay at hospital registered by interview at follow up visits) The outcome was correctly specified in the protocol paper and analysis plan (doi: 10.1186/s12889-019-7813-y)
Time frame: Enrolment to end of study (longest follow-up 2 years)
Acute adverse reactions
Health center consultations and illness registered through follow-up visits
Time frame: One-two months after a child is included in the study
Changes to the Respiratory and Gut Microbiome
Among 100 children enrolled in the OPV or corresponding control arm (Weighing-OPV), a nasal swab and a rectal swab will be collected at enrolment and 2 months later to assess effects of campaign OPV on the microbiome.
Time frame: Two months after a child is included in the study
Plan to share: No
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bandim Health Project